Smartlab Europe

HMS launches IntegritySource payment integrity suite for healthcare payers

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

It’s Time for the 3rd Generation of Patient Recruitment

Key Takeaways 80% of clinical trials experience enrolment delays and massive...

Driving Documentation Integrity Through Structured Drug Data

Establishing a robust framework for regulatory success requires moving beyond fragmented information silos toward a unified, digital-first approach. Comprehensive oversight of the pharmaceutical lifecycle depends on the ability to transform raw information into actionable insights, ensuring that every data point contributes to a larger narrative of safety and efficacy. By prioritizing specialized platforms that aggregate and organize complex information, organizations can achieve a level of transparency that satisfies the most stringent global standards while fostering a culture of continuous improvement.

Contamination Control with Toxicological Reference Data

Centralizing expert-verified toxicological datasets is now a critical requirement for modern pharmaceutical facilities operating under stringent global regulations. By transitioning from generic cleaning limits to precise Health-Based Exposure Limits derived from high-quality platforms, manufacturers ensure that cleaning validation protocols are scientifically sound and audit-ready. This approach integrates rigorous toxicological risk assessment into the broader contamination control strategy, safeguarding patient health while optimizing multi-product manufacturing efficiency and regulatory compliance.
- Advertisement -

HMS Holdings wholly owned subsidiary has launched HMS IntegritySource payment integrity suite for commercial and government healthcare payers.

Aimed to deliver ‘one data source, many solutions’, HMS IntegritySource’s key components include fraud, waste, and abuse identification and prevention; clinical program services; provider screening; automated and complex clinical reviews; financial audits; and Medicaid Recovery Audit Contractor (RAC) services.

HMS chief development officer Christina Dragonetti said, “HMS IntegritySource represents a significant step forward in providing a one-stop shop for payment integrity solutions for commercial and government payers.”

Enhancements used by commercial insurers enable government payers to improve the claims payment accuracy, boosting net return on investment from 3 to 1 to 10 to 1, according to the company.

Using information management and processing technology, HMS offers scalable services from supplemental to full outsourcing.

 

Latest stories

Related stories

It’s Time for the 3rd Generation of Patient Recruitment

Key Takeaways 80% of clinical trials experience enrolment delays and massive...

Driving Documentation Integrity Through Structured Drug Data

Establishing a robust framework for regulatory success requires moving beyond fragmented information silos toward a unified, digital-first approach. Comprehensive oversight of the pharmaceutical lifecycle depends on the ability to transform raw information into actionable insights, ensuring that every data point contributes to a larger narrative of safety and efficacy. By prioritizing specialized platforms that aggregate and organize complex information, organizations can achieve a level of transparency that satisfies the most stringent global standards while fostering a culture of continuous improvement.

Contamination Control with Toxicological Reference Data

Centralizing expert-verified toxicological datasets is now a critical requirement for modern pharmaceutical facilities operating under stringent global regulations. By transitioning from generic cleaning limits to precise Health-Based Exposure Limits derived from high-quality platforms, manufacturers ensure that cleaning validation protocols are scientifically sound and audit-ready. This approach integrates rigorous toxicological risk assessment into the broader contamination control strategy, safeguarding patient health while optimizing multi-product manufacturing efficiency and regulatory compliance.

Aligning Global Clinical Trials with Standardized Drug Data

Modern drug development necessitates a shift from fragmented data silos to a unified, intelligence-driven framework. Achieving global regulatory alignment requires a sophisticated approach to trial documentation standards and pharmaceutical regulatory governance, ensuring that clinical trial design remains robust across multiple jurisdictions. By leveraging standardized drug intelligence, sponsors can enhance submission readiness and maintain cross-border compliance, ultimately accelerating the delivery of life-saving therapies to patients worldwide.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »